Congenital Hyperinsulinism Treatment Market Size Report, 2032

Congenital Hyperinsulinism Treatment Market - By Drug Type (Diazoxide, Octreotide, Nifedipine, Glucagon), Route of Administration (Oral, Parenteral), Distribution Channel (Retail Pharmacies, Hospital Pharmacies), Global Forecast, 2023 - 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Global congenital hyperinsulinism treatment industry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Drug type trends

2.1.4&nbsp;&nbsp;&nbsp; Route of administration trends

2.1.5&nbsp;&nbsp;&nbsp; Ditribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Congenital Hyperinsulinism Treatment Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rising prevalence of congenital hyperinsulinism (CHI)

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing focus on personalized medicine

3.2.1.3&nbsp;&nbsp;&nbsp;Favorable government initiatives

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Limited approved treatment options

3.2.2.2&nbsp;&nbsp;&nbsp;High treatment cost

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug type

3.3.2&nbsp;&nbsp;&nbsp; By route of administration

3.3.3&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Company positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Congenital Hyperinsulinism Treatment Market Size and Forecast, By Drug Type (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by drug type

5.2&nbsp;&nbsp;&nbsp; Diazoxide

5.3&nbsp;&nbsp;&nbsp; Octreotide

5.4&nbsp;&nbsp;&nbsp; Nifedipine

5.5&nbsp;&nbsp;&nbsp; Glucagon

5.6&nbsp;&nbsp;&nbsp; Other drug types

Chapter 6&nbsp;&nbsp;&nbsp;Congenital Hyperinsulinism Treatment Market Size and Forecast, By Route of Administration (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by route of administration

6.2&nbsp;&nbsp;&nbsp; Oral

6.3&nbsp;&nbsp;&nbsp; Parenteral

Chapter 7&nbsp;&nbsp;&nbsp;Congenital Hyperinsulinism Treatment Market Size and Forecast, By Distribution Channel (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

7.2&nbsp;&nbsp;&nbsp; Retail pharmacies

7.3&nbsp;&nbsp;&nbsp; Hospital pharmacies

7.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 8&nbsp;&nbsp;&nbsp;Congenital Hyperinsulinism Treatment Market Size and Forecast, By Region (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by region

8.2&nbsp;&nbsp;&nbsp; North America

8.2.1&nbsp;&nbsp;&nbsp; U.S.

8.2.2&nbsp;&nbsp;&nbsp; Canada

8.3&nbsp;&nbsp;&nbsp; Europe

8.3.1&nbsp;&nbsp;&nbsp; Germany

8.3.2&nbsp;&nbsp;&nbsp; UK

8.3.3&nbsp;&nbsp;&nbsp; France

8.3.4&nbsp;&nbsp;&nbsp; Spain

8.3.5&nbsp;&nbsp;&nbsp; Italy

8.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

8.4&nbsp;&nbsp;&nbsp; Asia Pacific

8.4.1&nbsp;&nbsp;&nbsp; Japan

8.4.2&nbsp;&nbsp;&nbsp; China

8.4.3&nbsp;&nbsp;&nbsp; India

8.4.4&nbsp;&nbsp;&nbsp; Australia

8.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

8.5&nbsp;&nbsp;&nbsp; Latin America

8.5.1&nbsp;&nbsp;&nbsp; Brazil

8.5.2&nbsp;&nbsp;&nbsp; Mexico

8.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

8.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

8.6.1&nbsp;&nbsp;&nbsp; South Africa

8.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

8.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 9&nbsp;&nbsp;&nbsp;Company Profiles

9.1&nbsp;&nbsp;&nbsp; Crinetics Pharmaceuticals, Inc.

9.2&nbsp;&nbsp;&nbsp; Novartis AG

9.3&nbsp;&nbsp;&nbsp; Zealand Pharma A/S

9.4&nbsp;&nbsp;&nbsp; Rezolute, Inc.

9.5&nbsp;&nbsp;&nbsp; Hanmi Pharm.Co.,Ltd

9.6&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd

9.7&nbsp;&nbsp;&nbsp; Eli Lilly and Company

9.8&nbsp;&nbsp;&nbsp; Eiger BioPharmaceuticals

9.9&nbsp;&nbsp;&nbsp; AmideBio, LLC

9.10&nbsp;&nbsp;&nbsp; Xeris Pharmaceuticals, Inc. 
&nbsp;

Congenital Hyperinsulinism Treatment Market

Get a free sample of this report